Background An early and accurate diagnosis is crucial to provide optimal patient care in neurodegenerative diseases. Although an EEG shows advantages in availability and cost compared to the current diagnostic tools, it is not routinely used in clinical practice. Previous reviews have either focused on single disease populations and/or solely on resting state EEG. To evaluate the utility of EEG for early diagnosis and differential diagnosis, we conducted a systematic review across Alzheimers disease (AD), Frontotemporal Dementia (FTD) and Lewy Body Dementia (DLB). Methods We searched databases Pubmed, Cochrane, Web of Science, and Scopus for articles published from 2000 to 2023 investigating resting-state and task-based EEG-markers in biomarker-proven AD, FTD and DLB. Results Our search yielded a total of 12010 studies, of which 71 papers were eligible: 34 on AD, 18 on DLB and 9 on FTD. Slowing of the frequency spectrum was a common observation across diseases, achieving excellent sensitivity in AD and DLB. Research on FTD was limited and with varying results in the discrimination from healthy controls, although connectivity analysis and microstates are promising avenues. In differential diagnosis, both spectral and connectivity metrics show encouraging results. Task-based EEG emerges as a promising tool in early AD. Conclusion EEG shows promise as a cost-effective, non-invasive tool for early detection and differential diagnosis. Future research should aim to collect standardized data from multicentric cohorts, across multiple diseases and stages, and explore the neural underpinnings of these diseases, to improve interpretability of the findings.

The authors have declared no competing interest.

This study was funded by a doctoral grant of University of Antwerp

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript